Showing 4751-4760 of 8483 results for "".
- Syneron Launches PicoWay Picosecond Device for Pigmented Lesion Treatment and Tattoo Removalhttps://practicaldermatology.com/news/20141008-syneron_launches_picoway_picosecond_device_for_pigmented_lesion_treatment_and_tattoo_removal/2459094/Syneron Medical Ltd. launched its new PicoWay picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress, held in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a dual wavelength device, with 532nm and 1064nm wavelengths, which util
- Website Launches for Those Suffering from Acne Scarshttps://practicaldermatology.com/news/20141003-website_launches_for_those_suffering_from_acne_scars/2459097/A new website has launched to help those who suffer from the physical and emotional impacts of acne scarring. “A Scar Free Me” is the first of its kind online community that offers free resources and support for people coping with the aftermath of acne. Visitors can consult with skin car
- Ranbaxy Launches Absorica 25mg and 35mg Capsuleshttps://practicaldermatology.com/news/20141001-ranbaxy_launches_absorica_25mg_and_35mg_capsules/2459099/Ranbaxy Laboratories Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, launched Absorica (isotretinoin) 25 mg and 35 mg capsules into the US healthcare market. Absorica, according to the company, has become the most prescribe
- Mission Pharmacal Unveils New Lotion for Seborrheic Dermatitishttps://practicaldermatology.com/news/20140930-mission_pharmacal_unveils_new_lotion_for_seborrheic_dermatitis/2459100/To help bring a treatment option to people afflicted with common skin disorders including seborrheic dermatitis (SD), Mission Pharmacal Company has unveiled Ovace Plus Lotion (sodium sulfacetamide 9.8%). Ovace Plus Lotion joins Ovace Plus Wash (sodium sulfacetamide 10%) Cleansing Gel and Ovace Plus
- Foamix Pharmaceuticals Ltd. Closes Initial Public Offeringhttps://practicaldermatology.com/news/20140924-foamix_pharmaceuticals_ltd_closes_initial_public_offering/2459104/Foamix Pharmaceuticals Ltd. Closes Initial Public Offering A total of 6.7 million ordinary shares were sold at a price to the public of $6.00 per share. In addition, Foamix has granted the underwriters a 30 day option to purchase up to 1,005,000 additional ordinary shares. The sha
- AMA Calls for Design Overhaul of Electronic Health Records to Improve Usabilityhttps://practicaldermatology.com/news/20140917-ama_calls_for_design_overhaul_of_electronic_health_records_to_improve_usability/2459115/The AMA has called for solutions to EHR systems that have neglected usability as a necessary feature. Physicians need better designed EHR systems, the AMA has responded by releasing a new framework outlining eight priorities for improving EHR usability to benefit caregivers and patients.<
- MELA Sciences to Provide Corporate Overview at the Craig-Hallum Capital Group's 2014 Alpha Select Conferencehttps://practicaldermatology.com/news/20140917-mela_sciences_to_provide_corporate_overview_at_the_craig-hallum_capital_groups_2014_alpha_select_conference/2459118/Rose Crane, CEO of MELA Sciences, will provide a corporate overview at the Craig-Hallum Capital Group's 2014 Alpha Select Conference in New York City. Crane will discuss the latest FDA Pre-Market Approval of the MelaFind® System. To learn more go to:
- Promius Pharma, LLC: Finalist for PM360 Company of the Year Awardhttps://practicaldermatology.com/news/20140828-promius_pharma_llc_finalist_for_pm360_company_of_the_year_award/2459136/Promius Pharma, LLC has been named as a Trailblazer Company of the Year finalist by PM360, a publication that covers the pharmaceutical, biotech and medical device industries. Promius is one of three finalists in the category of Company of the Y
- Acyclovir Muco-Adhesive Buccal Tablet Offers a Novel Approach to Target HSVhttps://practicaldermatology.com/news/20140820-acyclovir_muco-adhesive_buccal_tablet_offers_a_novel_approach_to_target_hsv/2459141/Sitavig® (50mg acyclovir) Muco-Adhesive Buccal Tablet is a new treatment option for recurrent herpes labialis, offering a unique vehicle and delivery system. Sitavig, licensed to Innocutis by BioAlliance Pharma, uses proprietary Lauriad® delivery technology, which delivers a high and sustained conce
- Carma Laboratories Introduces New Carmex® Cold Sore Treatmenthttps://practicaldermatology.com/news/20140820-carma_laboratories_introduces_new_carmex_cold_sore_treatment/2459142/Carma Laboratories, Inc., the maker of Carmex® lip balm products, has launched the new Carmex® Cold Sore Treatment. This product features TriPLEX™ Formula advanced technology, which combines three different optical brightener and filler technologies that each provide unique appea